Sativex cost-effective in final NICE guideline on cannabis-based medicines

11 November 2019

Source MS Trust: Sativex is a cost-effective treatment for people with MS spasticity according to new guidance published today by NICE(link is external).  This reverses the decision made in draft guidance published earlier this year.

The guideline recommends that, providing the local NHS health authority is willing to pay for continued treatment, a 4-week trial of Sativex can be offered to people with moderate to severe MS-related spasticity which has not been improved by other treatments.  At the end of the trial, if their spasticity-related symptoms have improved by at least 20%, they can continue taking Sativex.  Read on. 

 

Blog categories: 

Category

Archive